Putting Testing at Oncologists’ Fingertips: Natera Integrates With OncoEMR

These days, it’s not enough in oncology to have great precision testing platform. If it’s too much work for physicians to order it, that technology can sit a shelf. Workflow integration is key—and that’s what makes the announcement that Natera’s oncology precision medicine offerings have been integrated into OncoEMR, Flatiron Health’s cloud-based electonronic medical record platform.

Flatiron announced the update in a statement Wednesday.¹

“We aim to equip providers with smart, connected tools that enhance care delivery without adding complexity,” Quincy Weatherspoon, vice president and general manager of point of care solutions at Flatiron Health, said in the statement. “Natera is a leader in precision medicine, and integrating the company’s oncology testing into OncoEMR exemplifies how thoughtful technology can drive efficiency at scale, support our provider networks and clinicians, and improve patient care and outcomes.”¹

OncoEMR, which reaches more than 1000 community oncology practices, was specifically designed for use in the business cancer care locations,¹ where minutes count. Embedding testing decisions into the EMR is essential, as molecular testing is no longer a one-time event. More treatment plans in blood cancers call for monitoring with minimal residual disease (MRD) testing, and the SERENA-6 trial demonstrated the value of repeat liquid biopsy to detect emergence of ESR1 mutations in breast cancer, before signs of progression appeared elsewhere.²

The integration offers oncologists “a unified ordering experience” for several popular Natera tests, including:

• Signatera, which offers ultrasensitive circulating tumor DNA (ctDNA) detection for MRD,
• Latitude, which offers fast results for MRD status based on a blood test,
• Altera, which performs comprehensive genomic profiling, and
• Empower, a hereditary cancer test.

Molecular testing can be suboptimal in community practice settings, even when patients are diagnosed with cancers where targeted therapies are readily available. A study published this year in Genetics in Medicine Open found that that mean number of days from disease diagnosis to the first biomarker test was 60 days for patients with non–small cell lung cancer, 156 days for those with prostate cancer, and 115 days among those with bladder cancer. In addition, investigators found variations by race and ethnicity, with Black patients with prostate or bladder cancer and Asian patients with bladder cancer seeing the longest delays.²

“Clinicians need testing solutions that are both scientifically rigorous and operationally seamless,” Minetta Liu, MD, chief medical officer of oncology for Natera, added in the statement. “This integration was designed with their daily workflows in mind—reducing administrative steps and accelerating access to molecular insights that can be used to guide confident treatment decisions.”

References

1. Natera integrates with Flatiron Health’s OncoEMR platform. News release. November 13, 2025. Accessed November 14, 2025. https://resources.flatiron.com/press/natera-integrates-with-flatiron-healths-oncoemr-platform
2. Dwyer Orr L, Mahmed S, Cline M, et al. Biomarker testing patterns among newly diagnosed with non-small cell lung, prostate, and bladder cancer. Genetics Med Open. 2025;3(suppl 2):102988. doi:10.1016/j. gimo.2025.102988